Interview with Jean-Philippe Duc, Country Manager, Amgen Czech Republic
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Address: Amgen Ltd. Klimentská 46 110 02 Prague 1,Czech Republic
Tel: +420 221 773 500
Web: http://www.amgen.cz/
Amgen commenced operations in Central and Eastern Europe on 1 May 2004, when the first eight countries of the region became members of the EU. Since then, Amgen’s Central European activities have constantly expanded. Among the company’s focus markets in the region are the Czech Republic, Poland, Hungary, Slovakia and Romania. Amgen is also active in Lithuania, Latvia, Estonia, Slovenia, Bulgaria.Amgen entered the Czech market in May 2004.The company is headquartered in Prague, but its team covers the whole territory of the Republic. At present, the Czech branch has over 60 employees.
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s orphan drug legislation as no standard pathway…
Jiří Lukeš, of B Braun Czech Republic, introduces the success of the affiliate he helped establish over 27 years ago, and why he feels that the local business is doing…
Petr Vaculík, country manager of PSI CRO, a privately owned Swiss clinical research organization (CRO), describes how the number of clinical trials is decreasing in the Czech Republic, although many…
Tamer Shawky, general manager Central Region for J&J Medical Devices, shares his first expectations arriving into the region three years ago, following a successful career in the Middle East and…
Olga Starobová, medical director of Syneos Health Czech Republic, walks us through the steps put in place to ensure successful synergies during the merger between INC Research and InVentiv Health,…
Kostas Deligiannis, general manager Eastern Europe for GE Healthcare (GEHC), outlines GE Healthcare’s commitment to the 20-country region under his remit, his priorities for greater collaboration between these countries, and…
Paul-François Cossa, country chair of Sanofi Czech Republic & Slovakia and General Manager CHC, reviews the outstanding performance of the company in 2019, breaks down his new vision for Sanofi…
Pavla Rozmarová, clinical research associate manager & regional OD for the Czech affiliate of German CRO Scope International, describes how the Czech clinical research landscape has evolved in the past…
Roman Badik, CEO of Enantis, the first biotechnology spin-off from Masaryk University in the Czech Republic, shares his vision of turning the company’s research breakthroughs into a self-sustaining business. Badik…
Augustin Bernát, general manager for the Czech affiliate of ResMed, a company whose cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases, discusses how…
Among the seven insurance funds in the Czech Republic, VZP is the largest with six million clients and the widest network of health service providers. David Šmehlík, the organisation’s deputy…
Martin Puchwein, country president for Novartis Group Czech Republic, and general manager for pharma, shares his perspectives on launching innovative drugs in the country, including some new therapeutic approaches such…
See our Cookie Privacy Policy Here